Recent insight into the pathophysiology of acute GVHD after allogeneic haematopoietic SCT has led to a growing interest in the role of natural killer (NK) cells. NK cell cytotoxicity is mainly regulated by the interaction of activating and inhibitory killer immunoglobulin-like receptors (KIRs) with their respective ligands. To investigate the impact of KIRs and their ligands on haematopoietic SCT outcome, we performed a retrospective study of 78 transfusion-dependent thalassaemia patients (median age 10 years, range 1-29 years) transplanted from an unrelated donor selected using high-resolution molecular typing for both class I and II loci after a myeloablative conditioning regimen. GVHD prophylaxis consisted of CsA, short-term MTX and antithymocyte globulin in all patients. We found that patients transplanted from donors homozygous for KIR haplotype A had a greater risk of developing grade II-IV acute GVHD compared with those transplanted from a donor carrying at least one B haplotype (hazard ratio ¼ 4.5, 99% confidence interval ¼ 1.2-17.1, P ¼ 0.003). Our study suggests that KIR genotyping of donor and recipient pairs could contribute to the identification of patients at high risk for developing severe complications of haematopoietic SCT and thus may help with the choice of intensity of GVHD prophylaxis.
Introduction
HLA class I molecules and killer cell immunoglobulin-like receptors (KIRs) are of pivotal importance for regulating natural killer (NK) cell function. 1 KIRs are encoded within a 100-200 kb region of the leucocyte receptor complex (LRC) on chromosome 19q13.4. The specificity of HLA class I molecules for inhibitory KIRs has been well established but has only been unequivocally documented for one activating KIR, namely KIR2DS1. 1, 2 The KIR gene family currently comprises 15 functional genes and 2 pseudogenes organized within the LRC as haplotypes. These haplotypes exhibit extensive variation in the number and type of KIR genes present, producing considerable diversity in the NK cell receptor repertoires. 3 Despite the variation in KIR gene composition and allelic polymorphism, KIR haplotypes can be broadly classified as A or B. Group A haplotype has a fixed gene content of seven KIR genes and two pseudogenes and includes a single activating gene (2DS4). Group B haplotype differs for both gene content and allelic polymorphism. In particular, group B haplotypes are distinguished by the presence of a variable number of KIR genes that are not components of group A haplotypes: the inhibitory KIR gene 2DL5 and different combinations of the activating KIR genes 2DS1, 2DS2, 2DS3, 2DS5 and 3DS1.
KIRs regulate the activity of NK cells through interaction with HLA class I molecules. HLA-C is the predominant ligand for the 2DL1, 2DL2 and 2DL3 inhibitory KIRs and the 2DS1 activating KIR. 1 The replacement of an amino acid residue at positions 77 and 80 of the HLA-C a-helix makes it possible to divide HLA-C molecules into two groups (C1 and C2), each one selectively recognized by a specific pair of activating/inhibitory KIRs. 4 Although recognition of specific HLA molecules by inhibitory KIRs has been firmly established, activating KIRs bind their putative ligands with low affinity. Several studies have investigated the influence of KIRs on the outcome of both related and unrelated haematopoietic SCT for haematological malignancies, leading to conflicting results. [5] [6] [7] The discrepancies observed in earlier studies may partially be explained by disease heterogeneity and differences in conditioning regimens and GVHD prophylaxis.
To investigate the impact of KIRs and their ligands on haematopoietic SCT outcome, we performed a retrospective study on a homogeneous cohort of thalassaemia patients transplanted from an HLA matched unrelated donor.
Patients and methods
Seventy-eight consecutive patients with transfusion-dependent b-thalassaemia were transplanted from an unrelated donor between September 1993 and December 2007. The aim of our study was to find associations between haematopoietic SCT outcome and (1) KIR genes or KIR haplotype combinations in donors and recipients; (2) donor KIR genotype and recipient HLA class I ligands. The study was approved by the local institutional review board of each participating Center; informed consent was obtained from all patients or parents or legal guardians. The clinical characteristics of donor-recipient pairs are reported in detail in Table 1 . All patients received similar conditioning regimens based on the combination of busulfan/treosulfan (BU/TREO), thiotepa (TT) and either CY (31 patients), or fludarabine (FLU, 47 patients). 8 All patients were transplanted with unmanipulated BM cells. GVHD prophylaxis consisted of CsA 3 mg/kg/day intravenously starting from day À2, and short-term MTX (15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6, þ 11). Patients were switched to oral CsA whenever they were able to tolerate oral medications. Median follow-up for surviving patients was 5 years (range 1-16 years).
Acute GVHD (aGVHD) was graded according to the internationally accepted criteria. 9 Graft rejection was defined as either the absence of haematopoietic reconstitution of donor origin on day þ 45 after the allograft (primary graft rejection) or as loss of donor cells after transient engraftment of donor-origin haematopoiesis, with return to transfusion dependence (secondary graft failure).
HLA and KIR gene typing
Patients and donors were HLA typed using high-resolution molecular techniques. Sixty-five donor/recipient pairs were matched for the HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1 and -DQB1 loci. Thirteen donor/recipient pairs had a disparity at the HLA-C locus, but both HLA-C molecules pertained to the same HLA-C ligand group.
The KIR genes 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3, 2DS1, 2DS2, 2DS3, 2DS4, 3DS1 were typed using the KIR-gene-specific primers described by Uhrberg et al., 10 with minor modifications. The KIR gene 2DS5 was typed using the primers described by Gagne et al.
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Combinations of donor 2DS2 and 2DS1 activatory KIRs and patient C1 and C2 KIR ligands were analysed according to the model proposed by Cook et al., 6 whereas combinations of donor 2DL1, 2DL2, 2DL3 and 3DL1inhibitory KIRs and patient C1, C2 and Bw4 KIR ligands were analysed according to the model proposed by Hsu et al.
7
The influence on transplantation outcomes of recipient HLA class I KIR ligands (C1, C2, HLA-A11, -A3, -Bw4) was analysed either alone or in combinations with the single activatory and inhibitory KIRs of the donors.
Donors and recipients were divided into two groups according to combinations of groups A and B KIR haplotypes: those homozygous for KIR haplotype A (AA) and those either heterozygous or homozygous for KIR haplotype B (AB þ BB). The different donor-recipient combinations of groups A and B KIR haplotypes were analysed for their correlation with different clinical outcomes.
Statistical analysis
The clinical and demographic variables shown in Table 1 [donor and recipient sex, age, Pesaro risk class at haematopoietic SCT, 12 human CMV serology, conditioning regimen, marrow cell dose infused, presence of HLA class I disparity, HLA-DPB1 disparity, classified in one of the three categories according to the identity or degree of permissivity in case of disparity 13, 14 ] were analysed for their potential impact on outcome. All variables were analysed using Fisher's twosided exact test or the w 2 -test, as appropriate. Bonferroni's correction was used for multiple comparisons. Variables with a P-value o0.2 were included in multivariate analysis using the Cox proportional hazards regression model. 15 P-values p0.01 were considered statistically significant (see Table 1 ). Survival analyses were performed using the Kaplan-Meier method. OS and thalassaemia-free survival (TFS) were defined as the time from diagnosis to death from any cause or to the first event (death or graft failure whichever occurred first), respectively, or to the last follow-up. The cumulative incidence of aGVHD, severe aGVHD and aGVHD-related mortality was calculated taking into the competing risks (either death or graft failure). The significance of the differences between curves was established using the logrank test. All statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software, version 14.0 (SPSS, Chicago, IL, USA).
Results

Clinical outcome
The clinical details and results obtained in our patients are reported in Table 1 . The 5-year OS and TFS probabilities for the whole cohort of patients were 89.8% (70/78) and 76.9% (60/78), respectively. Twenty-six patients (33.3%) developed grade II-IV aGVHD; eight of them (10.2%) experienced grade III-IV aGVHD. Nine patients (11.5%) rejected the allograft and eight (10.2%) died of transplantation-related complications. Six out of these eight patients died of causes related to aGVHD occurrence, one died of liver failure secondary to chronic GVHD, and one of CMV-related interstitial pneumonia.
Single KIR receptors
The gene frequencies in our cohort were similar to those reported in other Caucasoid populations. 16, 17 Of the 14 KIR genes analysed, the framework genes 2DL4, 3DL2 and 3DL3 were present in all donor/recipient pairs and 2DL1 was present in 151 of the 156 subjects (97%) examined. Most variations were observed for the number 
Recipient KIR ligands
The HLA-C KIR ligand was studied in all 78 donor/ recipient pairs: 25.6% (20/78) were C1/C1 homozygotes (both the donor and the recipient had HLA-Cw Asn80 ), 29.5% (23/78) were C2/C2 homozygotes (both the donor and the recipient had HLA-Cw Lys80 ) and 44.9% (35/78) were C1/C2 heterozygotes (donor and/or recipient expressed HLA-Cw antigens pertaining to both groups).
A significant correlation was observed between C1/C1 and C2/C2 homozygosity and occurrence of rejection. In fact, all 9 patients (9/43, 20.9%) who rejected the allograft were either C1/C1 or C2/C2 homozygotes, whereas none of the 35 C1/C2 heterozygotes experienced graft failure (HR ¼ 9.1, 99% CI ¼ 0.01-1.8, P ¼ 0.01, log rank ¼ 0.005).Univariate analysis did not reveal any correlation between the different combinations of HLA-C KIR ligands and either OS, TFS, mortality or aGVHD, although the latter was more frequent in the C1/C2 group.
KIR haplotypes
Twenty-one patients (26.9%) and 27 (34.6%) donors were homozygous for KIR haplotype A, the remaining donors and recipients being either BB homozygous or AB heterozygous. The KIR haplotype frequencies observed in our cohort of patients were similar to those reported in other populations. 16, 18 Fifteen of the 26 patients (57.7%) who developed grade II-IV aGVHD had been transplanted from donors homozygous for KIR haplotype A (HR ¼ 4.5, 99% CI ¼ 1.2-17.1, P ¼ 0.003, log rank ¼ 0.002). Moreover, the donors of seven of the eight patients who developed grade III-IV aGVHD were homozygous for KIR haplotype A (HR ¼ 7.0, 99% CI ¼ 1.3-37.5, P ¼ 0.01, log rank o0.001) (see also Figures 1a and b) . Five of the six patients who died of aGVHD had been transplanted from a donor carrying the AA haplotype (Figure 1c) .
When both donors and recipients were homozygous for the A haplotype (n ¼ 7), the risk for aGVHD was considerably increased: indeed, six out of the seven (85.7%) recipients developed aGVHD; vice versa in the group of 37 donor/recipient pairs with AB or BB haplotypes, the risk of grade II-IV aGVHD was low (HR ¼ 15.3, 99% CI ¼ 0.9-268.2, Po0.01), none of the patients experiencing severe aGVHD. No statistically significant association was observed between the different KIR haplotypes and rejection. Interaction between donor KIRs and recipient HLA class I ligands The effects of different combinations of donor KIRs and recipient C1 and/or C2 ligands were analysed using the model proposed by Cook et al. 6 for the activating KIRs and the 'missing KIR ligand' theory proposed by Hsu et al. 7 for the inhibitory KIRs. None of the combinations examined correlated with an increased risk for aGVHD (see Table 1 ).
Discussion
Several studies have investigated the influence exerted by KIRs and their ligands on haematopoietic SCT outcome, but the results remain conflicting. Dissecting the relative contribution of HLA, KIRs and their interactions in unrelated haematopoietic SCT is certainly challenging. Coupled with the genetic polymorphism is the complexity of the interactions between the different types of KIRs and their ligands, which, still today, remain poorly understood, especially those of activating KIRs. The reliability and soundness of the results deriving from such studies are further complicated by the large number of variables potentially influencing the clinical outcomes, especially when haematopoietic SCT is performed for haematological malignancies. Thalassaemia recipients of HLA-identical unrelated haematopoietic SCT represent a more homogeneous cohort in terms of primary disease, myeloablative conditioning regimen, stem cell source and GVHD prophylaxis, offering a better model for the evaluation of immunogenetic factors in transplantation outcome.
We found that patients transplanted from donors homozygous for KIR haplotype A (AA) had a fourfold risk of developing grade II-IV aGVHD and a sevenfold risk of developing severe (that is grade III-IV) aGVHD (Figures 1a and b) . Five of the six patients who died of aGVHD-related causes were transplanted from donors with the AA haplotype (Figure 1c) .
Our findings are in agreement with those of Ludajic et al. 19 who reported an increased risk for aGVHD when donors and recipients were homozygous for KIR haplotype A. The A haplotype only includes one stimulatory KIR (2DS4), which in most cases is not expressed on the NK cell membrane. 20 As available evidence indicates that the lytic activity of NK cells results from the balance between inhibitory and activating signals, it can be expected that the higher the number of activating genes in the KIR haplotype, the greater the ability of NK lymphocytes to exert their cytotoxic effects. As NK cells are able to kill haematopoietic-derived targets, including antigen-presenting cells (APC), donors expressing only the A haplotype could display a lower efficiency in killing recipient APC. These cells, in turn, could trigger donor T-lymphocytes into activation of the first step of the pathological cascade leading to aGVHD occurrence. 21 Zaia et al. 22 suggested that the increased expression of activating KIR receptors confers better protection against the reactivation of CMV and other viral infections, commonly recognized for promoting aGVHD. 23 In our study, the risk for severe aGVHD was remarkably low in patients transplanted from donors carrying haplotypes with a higher number of activating KIRs (Figure 1b ). This finding is further supported by the increased incidence of aGVHD observed in patients who received a graft from donors with low frequencies of the 2DS1, 2DS2, 2DS3 and 3DS1 activating KIR genes (data not shown). Altogether, these data show concordance with the results reported in the setting of haploidentical allogeneic haematopoietic SCT, [24] [25] [26] where NK alloreactive cells do not only exert their activity against tumour (GVL effect) or virally infected cells but also confer protection against aGVHD, through depletion of host APC. 24 In view of the complexity of KIR genes and ligands in humans, we cannot formally exclude a possible role played by inhibitory genes present in haplotype B and not in haplotype A.
Another interesting finding of our study is that all nine patients who experienced rejection were either C1 or C2 homozygotes. The strong association observed between C1 or C2 homozygosity and graft failure was confirmed in multivariate analysis (P ¼ 0.01). Conversely, none of the 35 recipients heterozygous for C1 and C2 groups experienced rejection. These data confirm the results of our earlier report on a more limited cohort of transplanted thalassaemia patients. 27 No correlation with rejection/graft failure was observed for the other immunogenetic factors analysed (activatory or inhibitory KIRs, KIR haplotypes, KIR ligands). Recent medical advances in the conventional treatment of thalassaemia patients are not only associated with enhanced life expectancy but also with less ironoverload related complications that negatively affect the quality of life. 28 Also in view of these significant achievements, every effort should be made to reduce the risk of transplantation-related mortality following haematopoietic SCT, largely caused by severe, treatment-refractory aGVHD. Our study suggests that, besides HLA-matching, KIR genotyping and analysis of HLA-C ligands of donor and recipient pairs can contribute to pre-transplantation risk assessment, favouring a more accurate counselling, and may prove to be precious to guide physicians in the choice of intensity of conditioning and GVHD prophylaxis for haematopoietic SCT in thalassaemia patients.
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